stonks4u
Sign up free
PALI logo

PALI Palisade Bio, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$2.14
-0.01 (-0.47%)

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integri…

Market Cap: $371.46Mwww.palisadebio.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

110
110
Aug 17Aug 17

Quote

Day Range
$2.06 – $2.15
52-Week Range
$0.53 – $2.86
Volume
$1.61M
Market Cap
$371.46M
50-Day Avg
$1.95
200-Day Avg
$1.93
Prev Close
$2.15
Open
$2.10

Valuation & Ratios

P/E Ratio
-7.83
EPS
$-0.30
P/B Ratio
1.01
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
28.95
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-13.0%
Return on Assets
-12.5%
FCF Yield
-8.3%
EV/EBITDA
0.15

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-16.78M$-0.30
2024$0.00$-14.44M$-10.19
2023$250.0K$-12.30M$-27.01
2022$0.00$-14.26M$-16.53
2021$0.00$-26.62M$-2144.25

Social Signal Score

60
5d
61
1 mentions
—
30d
60
1 mentions
—
60d
60
1 mentions
—
90d
60
1 mentions
—
news: 1

Earnings

Mon, Nov 9(in 3 months)

Consensus estimate $-0.06 per share

3of 7 quarters beat consensus

Typical surprise -18.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 10$-0.05 vs $-0.05beat
  • Tue, May 12$-0.05 vs $-0.04miss
  • Mon, Mar 23$-0.04 vs $-0.02miss
  • Mon, Nov 10$-0.38 vs $-0.32miss
  • Mon, Aug 11$-0.58 vs $-0.48miss
  • Mon, May 12$-0.47 vs $-0.84beat

Estimates and results for PALI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by PALI officers and directors.

Bought
$278k

10 trades

Sold
$420k

4 trades

  • Baltera Robert Jr.bought
    director·25,000 @ $1.96·$49k·Jul 9, 2026·filing
  • Baltera Robert Jr.bought
    director·20,000 @ $1.99·$40k·Jul 8, 2026·filing
  • Baltera Robert Jr.bought
    director·30,000 @ $2.03·$61k·Jul 7, 2026·filing
  • Jones Mitchell Lawrencesold
    Chief Medical Officer·51,880 @ $2.05·$107k·Jul 7, 2026·filing
  • Finley John Davidsold
    director, officer: CEO, CFO·146,798 @ $2.07·$303k·Jul 7, 2026·filing
  • Baltera Robert Jr.bought
    director·20,000 @ $2.05·$41k·Jul 6, 2026·filing
  • Baltera Robert Jr.bought
    director·10,000 @ $1.98·$20k·Jul 2, 2026·filing
  • Baltera Robert Jr.bought
    director·20,000 @ $1.98·$40k·Jul 1, 2026·filing

86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

PALIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsdefenseworld.net·6h ago·Positive

    Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $9.00 Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has received a consensus rating of "Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the

    View source ↗